Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

COVID-19 blood-thinner trials and LY-CoV555 trials paused for futility

By Brian Buntz | December 23, 2020

coronavirus COVID-19 Pfizer

[Photo by Fusion Medical Animation on Unsplash]

NIH has paused enrollment in three clinical trials for COVID-19 patients taking full doses of anticoagulants. The studies found that, for COVID-19 patients requiring intensive care unit support, anticoagulants did not reduce their need for organ support. Independent boards overseeing the trials could not rule out the potential for harm for such patients taking anticoagulants. 

The studies, which include the REMAP-CAP, ACTIV-4 and ATTACC trials, will continue testing high doses of anticoagulants in moderately ill hospitalized COVID-19 patients, according to an NIH statement. 

A related trial, ACTIV-3, was halted for futility for patients taking the neutralizing monoclonal antibody, LY-CoV555 (bamlanivimab) from Eli Lilly (NYSE:LLY). That study administered the drug in conjunction with remdesivir for hospitalized COVID-19 patients without end-organ failure, according to Physician’s Weekly. 

Prior research related to LY-CoV555 associated the antibody with reduced viral load, hospitalizations and emergency department visits for COVID-19 patients. The product received emergency use authorization from the FDA in November. 

The NIH statement stressed that anticoagulants still offer potential for COVID-19 patients. Some hospitals have aggressively used anticoagulants to treat critically ill COVID-19 patients. Because the virus can trigger inflammation and blood clots, blood thinners could prevent related adverse events such as stroke, heart attack and lung failure.  

Tell Us What You Think! Cancel reply

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards